Cancer CommunicationsPub Date : 2026-11-12eCollection Date: 2026-01-01DOI: 10.34133/cancomm.0062
Yaqiu Wang, Thirumala-Devi Kanneganti
{"title":"Leveraging Innate Immune and Metabolic Cell Death Pathways in Cancer Therapies.","authors":"Yaqiu Wang, Thirumala-Devi Kanneganti","doi":"10.34133/cancomm.0062","DOIUrl":"https://doi.org/10.34133/cancomm.0062","url":null,"abstract":"<p><p>Cancer cells evade cell death, and overcoming this resistance has been a fundamental challenge in cancer treatment. Innate immunity is critical in detecting cellular alterations, including those that accompany malignant transformation. Furthermore, innate immune signaling can activate tumor cell-intrinsic cell death pathways and immune-mediated killing to eliminate cancer cells. Several cell death pathways that are relevant to cancer have been defined, and we have broadly categorized these as caspase-dependent and caspase-independent pathways to reflect the key mechanistic difference between these groups for this discussion. The caspase-dependent pathways are genetically regulated by caspases; these include apoptosis, pyroptosis, and PANoptosis, which require caspases, and the contrasting pathway necroptosis, which is initiated in the absence of caspase-8. In contrast to caspase-dependent pathways, the caspase-independent pathways are driven by disruption of essential metabolic processes and include ferroptosis, disulfidptosis, cuproptosis, and mitoxyperilysis. Apoptosis is nonlytic, while all other pathways discussed here are lytic. Lytic cell death can involve the release of damage-associated molecular patterns (DAMPs) or cytokines that can further amplify innate immune cell death responses and paracrine PANoptosis, contributing to a sustained pro-inflammatory environment. Cancer cells vary widely in their expression of cell death mediators, leading to differing sensitivities to these cell death pathways. This heterogeneity represents both a therapeutic challenge and opportunity: inflammatory cell death within the tumor microenvironment is a double-edged sword, priming antitumor immunity in some contexts while fueling immunosuppression in others. In this review, we describe the cell death pathways relevant to cancer, highlighting recent advances in our mechanistic understanding of these pathways and discussing how this informs therapeutic targeting in cancers. Overall, a thorough understanding of innate immune responses in cancer cell death and the immunological consequences are essential to leverage these mechanisms to inform biomarker-guided patient stratification and develop next-generation cancer therapies.</p>","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"46 ","pages":"0062"},"PeriodicalIF":28.4,"publicationDate":"2026-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13755560/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149402177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Combined Immunotherapy and Hybrid Dose-Fraction Radiotherapy for Driver-Negative Metastatic NSCLC: A Phase II Trial with Parallel Preclinical Studies.","authors":"Ziye Li, Xiaoyang Li, Xiaoying Wei, Lejie Cao, Junqiang Zhang, Jianguo Wang, Yuan He, Anqi Hu, Lei Liu, Bing Yan, Congyu Wang, Hongxia Li, Ping Zeng, Jingjing Cheng, Anlin Wang, Jun Ma, Huailing Xia, Haibo Wu, Daqing Xia, Fengshou Jiang, Dan Xie, Dong Qian","doi":"10.34133/cancomm.0065","DOIUrl":"10.34133/cancomm.0065","url":null,"abstract":"<p><p><b>Background:</b> Immune checkpoint inhibitor (ICI)-based chemoimmunotherapy has become a standard first-line treatment for patients with driver-negative metastatic non-small cell lung cancer (NSCLC), but the clinical benefit is limited. Radiotherapy has potential antitumor immunomodulatory effects, but the optimal dose and fractionation remain unclear. <b>Methods:</b> This single-arm, multicenter, prospective, phase II trial enrolled patients with stage IV driver-negative NSCLC who received first-line chemoimmunotherapy. During the ICI maintenance phase, patients received hybrid dose-fraction radiotherapy (Hybrid-RT): stereotactic ablative body radiotherapy (SABR) to targetable lesions and low-dose radiotherapy (LDRT) to other sites. Patients restaged to stage III disease after chemoimmunotherapy received short-course hypofractionated radiotherapy to all residual lesions. The primary endpoint was 1-year progression-free survival (PFS) rate. The secondary endpoints included 1-year overall survival (OS) rate, objective response rate, and safety. Parallel preclinical mechanistic studies were performed in a murine model. <b>Results:</b> A total of 83 patients were enrolled from 2022 May 9 to 2023 December 31. The 1-year PFS rate was 54.2% (median PFS 16.1 months; 95% confidence interval [CI] 11.4 to 19.2 months), meeting the primary endpoint. The 1-year OS rate was 83.1% (median OS 29.3 months; 95% CI 21.9 months to not reached), and treatment was well tolerated. Peripheral immune profiling showed posttreatment expansion of cytotoxic CD8<sup>+</sup> T cells and natural killer (NK) cells associated with promising clinical efficacy. In the murine model, ICI plus Hybrid-RT (IHBRT) induced a division of labor between CD8<sup>+</sup> T and NK cells. At LDRT lesions, it facilitated both C-X-C motif chemokine receptor 3 (Cxcr3)-mediated recruitment of cytotoxic CD8<sup>+</sup> T cells and natural killer group 2 member D-mediated NK cell cytotoxicity. At SABR lesions, Cxcr3-mediated CD8<sup>+</sup> T cells played a predominant role, whereas NK cells contributed minimally. Moreover, IHBRT suppressed secreted phosphoprotein 1 positive (Spp1<sup>+</sup>) macrophages and relieved immunosuppression. <b>Conclusions:</b> Clinically, IHBRT demonstrates promising efficacy and a manageable safety profile in driver-negative metastatic NSCLC. Preclinically, it induces a functional division of labor between CD8<sup>+</sup> T and NK cells to activate antitumor immune cytotoxicity, and suppresses Spp1<sup>+</sup> macrophages, thereby relieving immunosuppression. <b>Trial registration:</b> This trial was registered at ClinicalTrials.gov (Identifier: NCT05348668). Date of registration: 2022 April 26.</p>","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"46 ","pages":"0065"},"PeriodicalIF":28.4,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13748629/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149385528","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer CommunicationsPub Date : 2026-11-10eCollection Date: 2026-01-01DOI: 10.34133/cancomm.0068
Ying Liu, Xiangjiao Meng, Yan Yu, Jianhua Chen, Runxiang Yang, Laiyu Liu, Yanqiu Zhao, Ruifen Tian, Dianming Li, Ruiling Ning, Qingshan Li, Guowu Wu, Li Wang, Xianghui Duan, Xuejie Guo, Yan Hu, Weili Liu, Haifeng Liu
{"title":"Dirozalkib versus Crizotinib in Advanced Anaplastic Lymphoma Kinase Inhibitor-Naïve <i>ALK</i>-Positive Non-Small-Cell Lung Cancer: A Multicenter, Randomized Phase III Trial.","authors":"Ying Liu, Xiangjiao Meng, Yan Yu, Jianhua Chen, Runxiang Yang, Laiyu Liu, Yanqiu Zhao, Ruifen Tian, Dianming Li, Ruiling Ning, Qingshan Li, Guowu Wu, Li Wang, Xianghui Duan, Xuejie Guo, Yan Hu, Weili Liu, Haifeng Liu","doi":"10.34133/cancomm.0068","DOIUrl":"10.34133/cancomm.0068","url":null,"abstract":"<p><p><b>Background:</b> Dirozalkib is a highly selective anaplastic lymphoma kinase (<i>ALK</i>) inhibitor with intracranial antitumor activity against crizotinib-resistant mutations. This phase III trial evaluated dirozalkib versus crizotinib in patients with ALK inhibitor-naïve, <i>ALK</i>-positive, advanced non-small-cell lung cancer (NSCLC). <b>Methods:</b> In this multicenter, randomized, open-label DIAMOND-2 trial, adult patients with ALK inhibitor-naïve, <i>ALK</i>-positive, advanced NSCLC who either had received no prior systemic therapy or had experienced disease progression or intolerance after one prior chemotherapy regimen were randomly assigned 1:1 to dirozalkib (500 mg once daily) or crizotinib (250 mg twice daily). The primary end point was investigator-assessed progression-free survival (PFS). <b>Results:</b> Between 2022 January 24 and 2023 April 30, 275 patients were randomly assigned to receive dirozalkib (<i>n</i> = 137) or crizotinib (<i>n</i> = 138). As of 2025 May 31, the median follow-up durations were 32.8 and 31.6 months, respectively. Median investigator-assessed PFS was 29.5 (95% confidence interval [CI] = 20.3 to not reached) months with dirozalkib versus 12.9 (95% CI = 11.1 to 17.6) months with crizotinib (hazard ratio [HR] = 0.47, 95% CI = 0.34 to 0.66; <i>P</i> < 0.001). Blinded-independent-central-review-assessed PFS was also significantly prolonged with dirozalkib (median PFS, 27.5 versus 12.9 months; HR = 0.54, 95% CI = 0.39 to 0.74; <i>P</i> < 0.001). Grade ≥3 treatment-emergent adverse events (TEAEs) were less frequent with dirozalkib than with crizotinib (60.6% versus 72.5%), and TEAEs led to treatment discontinuation in 2.2% and 7.2% of patients, respectively. <b>Conclusions:</b> Dirozalkib significantly improved PFS versus crizotinib, with a manageable safety profile, supporting its use as a first-line therapy for <i>ALK</i>-positive advanced NSCLC. <b>Trial registration:</b> This trial was registered at ClinicalTrials.gov on 2022 January 24 (NCT05204628).</p>","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"46 ","pages":"0068"},"PeriodicalIF":28.4,"publicationDate":"2026-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13748627/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149385437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer CommunicationsPub Date : 2026-11-03eCollection Date: 2026-01-01DOI: 10.34133/cancomm.0061
Xiao-Peng Tian, Jun Cai, Shu-Yun Ma, Yu Fang, Hui-Qiang Huang, Tong-Yu Lin, Hui-Lan Rao, Mei Li, Zhong-Jun Xia, Tie-Bang Kang, Dan Xie, Qing-Qing Cai
{"title":"Erratum to \"BRD2 induces drug resistance through activation of the RasGRP1/Ras/ERK signaling pathway in adult T-cell lymphoblastic lymphoma\".","authors":"Xiao-Peng Tian, Jun Cai, Shu-Yun Ma, Yu Fang, Hui-Qiang Huang, Tong-Yu Lin, Hui-Lan Rao, Mei Li, Zhong-Jun Xia, Tie-Bang Kang, Dan Xie, Qing-Qing Cai","doi":"10.34133/cancomm.0061","DOIUrl":"10.34133/cancomm.0061","url":null,"abstract":"<p><p>[This corrects the article DOI: 10.1002/cac2.12039.].</p>","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"46 ","pages":"0061"},"PeriodicalIF":28.4,"publicationDate":"2026-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13728228/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149318367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Spatiotemporal Analysis of Molecular Continuity in Pathogenesis of Squamous Cell Carcinoma: From Normal Epithelium to Precancerous Lesions and Carcinoma.","authors":"Lan Lan, Xinyu Wang, Xiaoqi Jiang, Xiangyi Lin, Yancheng Lai, Wen Tan, Shaosen Zhang, Dongxin Lin, Chen Wu","doi":"10.34133/cancomm.0051","DOIUrl":"10.34133/cancomm.0051","url":null,"abstract":"<p><p>Squamous cell carcinomas (SCCs) develop from the stratified epithelia of the esophagus, head and neck, lung, and skin, providing a tractable model to investigate how altered epithelial fields progress toward invasive cancer. Across SCC subtypes, evolution often begins before overt malignancy, with age- and exposure-associated mutant clones expanding within histologically normal epithelia. As lesions advance, early driver selection becomes coupled to copy number alterations, chromosomal instability, and epigenetic remodeling, whereas later stages are shaped by branching diversification, cellular plasticity, and regionally constrained selection. Despite tissue-specific differences, several recurrent principles emerge, including clonal expansion within mutated normal fields, transition bottlenecks marked by genome-scale instability, and the spatial organization of subclonal architecture and invasive-front states. In this review, we synthesize recent progress in the temporal ordering and spatial patterning of SCC evolution and discuss how genetic alterations, epigenetic remodeling, and tissue ecology jointly drive disease progression. We further highlight the implications for early interception, biomarker development, immune evasion, and evolution-informed prevention and therapy.</p>","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"46 ","pages":"0051"},"PeriodicalIF":28.4,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13678079/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149223426","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer CommunicationsPub Date : 2026-10-19eCollection Date: 2026-01-01DOI: 10.34133/cancomm.0059
Gae Hoon Jo, Sohyun Hwang, Bernhard Scheiner, Seonjeong Woo, Won Suk Lee, Beodeul Kang, Jung Sun Kim, Ho Yeong Lim, Chansik An, Dong Yun Kim, Inyoung Kim, Dong-Hyuk Heo, Matthias Pinter, Beom Kyung Kim, Chan Kim, Hong Jae Chon
{"title":"CAPTYN, a Blood-Based Machine-Learning Model Predicting Clinical Benefit of Atezolizumab-Bevacizumab in Hepatocellular Carcinoma: Validation in the IMbrave150 Trial.","authors":"Gae Hoon Jo, Sohyun Hwang, Bernhard Scheiner, Seonjeong Woo, Won Suk Lee, Beodeul Kang, Jung Sun Kim, Ho Yeong Lim, Chansik An, Dong Yun Kim, Inyoung Kim, Dong-Hyuk Heo, Matthias Pinter, Beom Kyung Kim, Chan Kim, Hong Jae Chon","doi":"10.34133/cancomm.0059","DOIUrl":"10.34133/cancomm.0059","url":null,"abstract":"","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"46 ","pages":"0059"},"PeriodicalIF":28.4,"publicationDate":"2026-10-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13678081/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149223410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Metabolic Competition-Driven Antitumor Immunity of <i>glpX</i>-Deficient Engineered <i>Salmonella</i> via Glucose Deprivation and STING Activation in Bladder Cancer.","authors":"Leyang Wu, Xinyue Qiao, Wanru Wang, Jiahui Qiu, Xiao Dong, Liyuan Qiao, Chengxuan Lei, Xiaoxin Zhang, Ying Sun, Chenyang Li, Bohao Wang, Zengzheng Du, Heng Liu, Zhengbing Lv, Xiaofeng Jiang, Zichun Hua","doi":"10.34133/cancomm.0060","DOIUrl":"10.34133/cancomm.0060","url":null,"abstract":"<p><p><b>Background:</b> Bacteria-mediated cancer therapy is emerging as a promising approach due to its low cost, scalability, and sustained efficacy. While bacterial immunomodulation has been extensively studied, the role of bacterial metabolic competition, particularly for glucose, in tumor suppression remains unclear. We aimed to investigate how engineered <i>Salmonella</i> strains exploit metabolic competition to trigger antitumor immunity and improve therapeutic outcomes in bladder cancer models. <b>Methods:</b> Using genetic screening, we generated a gluconeogenesis-deficient <i>Salmonella</i> strain, the AISIH strain with the <i>glpX</i> gene knocked out (GLA1), with enhanced glucose uptake. In vitro and in vivo assays were performed to assess tumor cell glucose deprivation, mitochondrial stress, cytosolic mitochondrial DNA (mtDNA) release, and activation of the cGAS/STING pathway. An engineered strain, GLA2, was generated from the AISIH strain by knockout of the <i>glpX</i> gene and was subsequently further engineered to locally deliver an anti-tumor necrosis factor-α (TNF-α) nanobody under quorum-sensing control. Efficacy was evaluated in subcutaneous and orthotopic bladder cancer models, with analysis of tumor-infiltrating immune cells, dendritic cell (DC) maturation, and T cell priming. <b>Results:</b> GLA1 competitively depleted glucose in the bladder tumor microenvironment, inducing energy stress, mitochondrial damage, and mtDNA release, which noncanonically activated the STING pathway. This promoted type I interferon production, DC maturation, and antitumor immune responses. However, TNF-α-mediated vascular abnormalities limited efficacy. GLA2 normalized tumor vasculature via local anti-TNF-α delivery, enhancing nutrient competition and immune activation. Both strains markedly suppressed tumor growth, with GLA2 showing superior efficacy due to synergistic metabolic and immune reprogramming. <b>Conclusions:</b> This study demonstrates that bacterial competition for glucose is a pivotal mechanism of antitumor activity in bladder cancer, linking metabolic stress to STING-dependent immune activation. Engineered <i>Salmonella</i> strains that combine enhanced glucose uptake with local vascular normalization offer a robust platform for bladder cancer. These findings highlight a novel strategy to integrate microbial metabolic engineering with immune modulation, providing a foundation for precision bacteriotherapy in oncology.</p>","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"46 ","pages":"0060"},"PeriodicalIF":28.4,"publicationDate":"2026-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13669507/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149215038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Cancer CommunicationsPub Date : 2026-10-09eCollection Date: 2026-01-01DOI: 10.34133/cancomm.0056
Yao Li, Hongwen Liu, Lei Xu, Lili Huang, Hui Xue, Tao Lu, Yuxuan Lin, Liangrui Chen, Jianwei Liu, Shilei Bai, Yong Xia, Lei Wang, Hui Dong, Feng Shen, Kui Wang
{"title":"Targeting TREM2<sup>+</sup> and TIMD4<sup>+</sup> Macrophages Reprograms the Tumor Microenvironment and Enhances PD-1 Blockade Efficacy in Intrahepatic Cholangiocarcinoma.","authors":"Yao Li, Hongwen Liu, Lei Xu, Lili Huang, Hui Xue, Tao Lu, Yuxuan Lin, Liangrui Chen, Jianwei Liu, Shilei Bai, Yong Xia, Lei Wang, Hui Dong, Feng Shen, Kui Wang","doi":"10.34133/cancomm.0056","DOIUrl":"10.34133/cancomm.0056","url":null,"abstract":"<p><p><b>Background:</b> Intrahepatic cholangiocarcinoma (ICC) is the second most common primary liver cancer. Macrophages are crucial components of the tumor microenvironment (TME). Triggering receptor expressed on myeloid cells 2-positive (TREM2<sup>+</sup>) macrophages have recently emerged as potent pro-tumor progress players in several cancers. However, the heterogeneity and tumor-promoting mechanisms of macrophages especially TREM2<sup>+</sup> macrophages in ICC remain systematically unexplored. Therefore, this study aimed to systematically elucidate the heterogeneity of macrophages in ICC, with a specific focus on the pro-tumor role of TREM2<sup>+</sup> macrophages. <b>Methods:</b> We collected tumor tissues, adjacent nontumor tissues, and tumor-adjacent border tissues from 16 ICC patients. These samples were subjected to single-cell RNA sequencing and spatial transcriptomic sequencing, followed by comprehensive analysis. The findings were further validated through flow cytometry, immunohistochemistry, multiplex immunofluorescence, and in vitro cellular assays. Furthermore, we established an ICC model using genetically engineered (<i>Trem2<sup>-/-</sup></i> ) mice as a validation cohort to corroborate the discoveries from human samples. <b>Results:</b> Macrophages are important prognostic factors in ICC, with functional heterogeneity. TREM2<sup>+</sup> macrophages in tumor tissues promote immune suppression by exhausting CD8<sup>+</sup> T cells and inducing the generation of regulatory T cells to produce. At the tumor border region, TREM2<sup>+</sup> macrophages enhance ICC invasion via the urokinase-type plasminogen activator-urokinase-type plasminogen activator receptor axis and induce hepatic stellate cell conversion to myofibroblastic cancer-associated fibroblast, forming a physical immune barrier that impedes CD8<sup>+</sup> T cell infiltration in tumor tissues. TIMD4<sup>+</sup> macrophages in adjacent tissues also suppress CD8<sup>+</sup> T cell function. Combining anti-Trem2 and anti-Timd4 with anti-Pd-1 antibodies significantly improved treatment outcomes in the ICC mice. <b>Conclusions:</b> TREM2<sup>+</sup> and TIMD4<sup>+</sup> macrophages are key regulators of the immunosuppressive TME in ICC. Targeting Trem2 and Timd4 enhances the effectiveness of anti-Pd-1 therapy in ICC mouse models.</p>","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"46 ","pages":"0056"},"PeriodicalIF":28.4,"publicationDate":"2026-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13650241/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149168730","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The Five-Decade Journey of Small Cell Lung Cancer.","authors":"Runzhi Chen, Chang Xue, Yi Zhong, Qing Huang, Qianyu Fan, Yuanxiang Li, Jingyi Wu, Shuang Dong, Xiaoyu Li, Tianlin Xiao, Sheng Hu","doi":"10.34133/cancomm.0052","DOIUrl":"10.34133/cancomm.0052","url":null,"abstract":"<p><p>Over the past 5 decades, small cell lung cancer (SCLC) has persisted as one of the most formidable malignancies, largely attributed to its aggressive early metastasis, limited therapeutic arsenal in both first-line and subsequent treatments, and rapid onset of treatment resistance. The dawn of a new era in the treatment of SCLC appeared in 2018, with the introduction of first-line chemotherapy combined with immune checkpoint inhibitors, as well as tarlatamab for later-line treatment. However, the improvements in survival, although tangible, were still unsatisfactory. Therefore, this review focuses on unraveling the mechanisms underlying cancer initiation, progression, and particularly metastasis, as well as emerging advances in molecular subtyping and drug resistance from the epigenetic perspective. Simultaneously, we outline their hallmark characteristics-high plasticity, heterogeneity, redundancy, and ambiguity driven by intercellular crosstalk under spatiotemporal dependency. Furthermore, we highlight the evolving progress of various successful drugs or therapeutic strategies and molecular biomarkers in clinical practice for SCLC, as well as promising agents under investigation. Finally, we also discuss how to leverage artificial intelligence and innovative biomedical technologies, as well as learn from various challenges in order to improve the therapeutic landscape of SCLC.</p>","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"46 ","pages":"0052"},"PeriodicalIF":28.4,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13639146/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"GULP1 Fuels Resistance to PD-1 Blockade through Lipid-Mediated Metabolic Reprogramming of Tumor-Associated Macrophages in Gastric Cancer.","authors":"Zihao Zhang, Wenxin Xu, Kuan Yu, Anran Bao, Yifan Cao, Mincheng Yu, Qiang Yu, Yufei Zhao, Liang Gong, Peiyi Xie, Zhenbin Shen, Jing Qin","doi":"10.34133/cancomm.0054","DOIUrl":"10.34133/cancomm.0054","url":null,"abstract":"<p><p><b>Background:</b> Immune checkpoint inhibitors targeting programmed cell death protein 1 (PD-1) have substantially improved the treatment of multiple cancers; however, only a small proportion of gastric cancer (GC) patients achieve durable clinical benefit. The underlying tumor-intrinsic mechanisms driving resistance to anti-PD-1 therapy remain poorly understood. This study aimed to identify key regulators of immunotherapy resistance in GC and to elucidate their functional and mechanistic roles. <b>Methods:</b> Transcriptomic data from anti-PD-1-responsive and anti-PD-1-resistant GC patients were analyzed and integrated with mouse model data and publicly available single-cell RNA sequencing datasets. Functional experiments, including in vitro assays and in vivo tumor models, were performed to validate candidate genes and explore their roles in tumor progression and immunotherapy resistance. <b>Results:</b> GULP PTB domain-containing engulfment adaptor 1 (GULP1) was identified as a key driver of resistance to anti-PD-1 therapy in GC. Elevated GULP1 expression was associated with poor prognosis and unfavorable clinical responses to PD-1 blockade. GULP1 promoted GC progression and attenuated the therapeutic efficacy of anti-PD-1 treatment. Functionally, GULP1 facilitated the accumulation and metabolic reprogramming of CD36<sup>+</sup> programmed death-ligand 1 (PD-L1)<sup>+</sup> tumor-associated macrophages (TAMs) by shaping a lipid-enriched tumor microenvironment, thereby impairing CD8<sup>+</sup> T-cell function. Mechanistically, GULP1 promoted insulin-induced gene 2 (INSIG2) palmitoylation through the recruitment of zinc finger DHHC-type palmitoyltransferase 8 (zDHHC8), resulting in sterol regulatory element-binding protein 1 (SREBP1) nuclear translocation and enhanced de novo fatty acid biosynthesis. Importantly, pharmacological inhibition of Gulp1 with glycyrrhizic acid significantly restored sensitivity to anti-PD-1 therapy in vivo. <b>Conclusions:</b> Collectively, these findings uncovered a previously unrecognized GULP1-fatty acid-CD36<sup>+</sup>PD-L1<sup>+</sup> TAM-CD8<sup>+</sup> T-cell axis that drove resistance to PD-1 blockade in GC, highlighting GULP1 as a promising therapeutic target and predictive biomarker for immunotherapy responsiveness.</p>","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"46 ","pages":"0054"},"PeriodicalIF":28.4,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13639144/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149104479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}